Enlivex Therapeutics Ltd.
NASDAQ Capital MarketTotal Valuation
Enlivex Therapeutics Ltd. carries a market capitalization of 10.20M, placing it among publicly traded companies globally. Its enterprise value stands at 161.84M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 10.20M |
| Enterprise Value | 161.84M |
Share Statistics
Enlivex Therapeutics Ltd. currently has 15.83M shares outstanding.
| Shares Outstanding | 15.83M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Enlivex Therapeutics Ltd. trades at a trailing price-to-earnings ratio of 0.01.
| PE Ratio | 0.01 |
| PS Ratio | N/A |
| PB Ratio | 0.09 |
| P/TBV Ratio | 0.09 |
| P/FCF Ratio | -1.62 |
| P/OCF Ratio | -1.61 |
Financial Position
Enlivex Therapeutics Ltd. maintains a current ratio of 193.24, meaning it holds 193.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 193.24 |
| Quick Ratio | 0.69 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | -0.04 |
| Interest Coverage | N/A |
Financial Efficiency
Enlivex Therapeutics Ltd. posts a return on equity of 126.17 and a return on invested capital of -1.53.
| Return on Equity (ROE) | 126.17 |
| Return on Assets (ROA) | 104.94 |
| Return on Invested Capital (ROIC) | -1.53 |
| Return on Capital Employed (ROCE) | 126.09 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Enlivex Therapeutics Ltd.'s stock has declined approximately -96.07961% over the past 52 weeks. The 50-day moving average sits at 1.93, while the 200-day moving average is 10.34.
| Beta (5Y) | N/A |
| 52-Week Price Change | -96.07961% |
| 50-Day Moving Average | 1.93 |
| 200-Day Moving Average | 10.34 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -14.67M, while operating income came in at -15.00M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -15.00M |
| Pretax Income | 1.62B |
| Net Income | 1.24B |
| EBITDA | -14.67M |
| EBIT | -15.00M |
| Earnings Per Share (EPS) | 775.87 |
Balance Sheet
Enlivex Therapeutics Ltd. holds 5.76M in cash and equivalents against 641,000.00 in total debt, resulting in a net debt position of -1.89M. Total book value stands at 1.93B, with working capital of 1.73B providing operational flexibility.
| Cash & Cash Equivalents | 5.76M |
| Total Debt | 641,000.00 |
| Net Debt | -1.89M |
| Equity (Book Value) | 1.93B |
| Book Value Per Share | 122.27 |
| Working Capital | 1.73B |
Cash Flow
Enlivex Therapeutics Ltd. produced -10.42M in operating cash flow over the past twelve months. After subtracting -68,000.00 in capital expenditures, free cash flow totaled -10.48M - equivalent to -6.58 per share.
| Operating Cash Flow | -10.42M |
| Capital Expenditures | -68,000.00 |
| Free Cash Flow | -10.48M |
| FCF Per Share | -6.58 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -6.22 |
| FCF Yield | -61.59 |
Stock Splits
Enlivex Therapeutics Ltd.'s most recent stock split took place on July 9, 2026 with a 15:1 split ratio.
| Last Split Date | 7/9/2026 |
| Split Ratio | 15:1 |
Scores
Enlivex Therapeutics Ltd. posts an Altman Z-Score of 1.80, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.80 |